Beijing Tiannuo Jiancheng Pharmaceutical Technology

Beijing Tiannuo Jiancheng Pharmaceutical Technology is a clinical-stage biotechnology company operating as a 50/50 joint venture between InnoCare Pharma and KeyMed Biosciences. Founded in 2017 and based in Beijing, the company specializes in the development of innovative antibody-based therapies for oncology and autoimmune disorders. Its primary clinical asset, ICP-B02 (CM355), is a CD20xCD3 bispecific antibody currently being evaluated in Phase 2 trials for relapsed or refractory B-cell non-Hodgkin lymphoma. Additionally, the company is advancing CM369, an anti-CCR8 monoclonal antibody for the treatment of various solid tumors. In January 2025, the company secured a strategic global licensing agreement with Prolium Bioscience for the development and commercialization of its lead candidate in non-oncology fields and oncology outside of Asia.